Lv11
60 积分 2022-10-14 加入
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
7小时前
待确认
Sotorasib approved for KRAS G12C-mutated non-small cell lung cancer
7小时前
求助中
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
1个月前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
1个月前
已完结
Uncommon de novo EGFRT790M-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment
5个月前
已完结
Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
5个月前
已完结
Genomic alterations in thyroid cancer: biological and clinical insights
5个月前
已完结
Molecular genetics and diagnosis of thyroid cancer
5个月前
已完结
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020
5个月前
已完结
Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced non-small cell lung cancer: results from a phase 2 pivotal study
9个月前
已完结
皖公网安备34019202002308
